{"id":251467,"date":"2024-03-06T00:00:00","date_gmt":"2024-03-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidcv0048-biopharma-venous-thromboembolism-epidemiology-2\/"},"modified":"2026-04-29T11:23:38","modified_gmt":"2026-04-29T11:23:38","slug":"epidcv0048-biopharma-venous-thromboembolism-epidemiology-epidemiology-dashboard","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcv0048-biopharma-venous-thromboembolism-epidemiology-epidemiology-dashboard\/","title":{"rendered":"Venous Thromboembolism &#8211; Epidemiology &#8211; Epidemiology Dashboard"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of <abbr title=\"venous thromboembolism\">VTE<\/abbr> comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of <abbr title=\"venous thromboembolism\">VTE<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.<\/p>\n<p>All forecast data are available on Clarivate\u2019s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr title=\"venous thromboembolism\">VTE<\/abbr> forecast answers the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of <abbr title=\"venous thromboembolism\">VTE<\/abbr> and the number of new diagnoses of <abbr title=\"venous thromboembolism\">VTE<\/abbr>?<\/li>\n<li>Of all people diagnosed with <abbr title=\"venous thromboembolism\">VTE<\/abbr>, how many in each country across the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"venous thromboembolism\">VTE<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following <abbr title=\"venous thromboembolism\">VTE<\/abbr> subpopulations:<\/p>\n<ul class=\"round-bullets\">\n<li>Top-line epidemiology \u2013 Diagnosed <abbr title=\"venous thromboembolism\">VTE<\/abbr> events.<\/li>\n<li>Key Populations \u2013 Diagnosed <abbr title=\"deep vein thrombosis\">DVT<\/abbr> events.<\/li>\n<li>Key Populations \u2013 Diagnosed <abbr title=\"pulmonary embolism\">PE<\/abbr> events.<\/li>\n<li>Diagnosed <abbr title=\"venous thromboembolism\">VTE<\/abbr> events by etiology.<\/li>\n<li>Diagnosed <abbr title=\"venous thromboembolism\">VTE<\/abbr> events by recurrence.<\/li>\n<li>Diagnosed <abbr title=\"deep vein thrombosis\">DVT<\/abbr> events by treatment scheme.<\/li>\n<li>Diagnosed <abbr title=\"pulmonary embolism\">PE<\/abbr>\u00a0events by treatment scheme.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251467","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-cardiovascular","biopharma-therapy-areas-venous-thromboembolism","biopharma-product-epidemiology","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251467","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251467\/revisions"}],"predecessor-version":[{"id":305229,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251467\/revisions\/305229"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251467"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}